COMMUNIQUÉS West-GlobeNewswire

Curium, in collaboration with nuclear cardiology leaders, announces immediate return of Thallous Chloride TI 201 Injection in the U.S. to support high-stakes cardiac imaging needs
27/07/2026
Reintroduction reflects clinician input and Curium investments to support reliable, long-term U.S. supply BOSTON, July 27, 2026 (GLOBE NEWSWIRE) -- Curium™ announced today the immediate reintroduction of Thallous [...]
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
27/07/2026
Proceeds to support ongoing late-stage global clinical development and commercialization preparation of dotinurad, a next-generation, once daily, oral URAT1 inhibitor with the potential to deliver best-in-class safety [...]
Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel
27/07/2026
New agreement secures flexible and scalable manufacturing to support the U.S. commercial and global clinical supply of miv-cel EMERYVILLE, Calif., and WALTHAM, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Kyverna [...]
Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process
27/07/2026
— First patient enrolled in Part B of Phase 2 ASCEND study enabled by availability of drug product from new manufacturing process — — Topline data from Part A of Phase 2 ASCEND study remains on track for end of year — [...]
FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
27/07/2026
– Approval expands colorectal cancer screening options for the up to 60 million Americans who are overdue for screening – – Medicare coverage and American Cancer Society guidance support broader access to blood-based [...]
Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting
27/07/2026
– Phase 2a study of CTEV in coronary artery bypass grafting (CABG) is expected to start this quarter – – Progression of CTEV into human study supported by positive preclinical results presented at multiple scientific [...]
Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer
27/07/2026
Dr. Zack brings more than 25 years of leadership in developing therapeutics for immune-mediated diseases Appointment strengthens Spero’s clinical leadership team as the Company advances SP001, a Phase 2-ready third- [...]
Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference
27/07/2026
SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of systemically delivered, [...]
Oak Hill Bio and Research Alliance Corporation III Announce Business Combination Agreement to Create Publicly Listed Rare Disease Biotechnology Company to Advance Antisense Oligonucleotide Therapy Rugonersen for Angelman Syndrome
27/07/2026
Transaction to provide Oak Hill Bio with approximately $175 million in gross proceeds, including $75 million of cash in Research Alliance Corporation III’s (Nasdaq: RACC) (“RACC”) trust account that is fully backstopped [...]
FLYTE Partners with 319 Golf Society and Named Exclusive Private Aviation Partner
27/07/2026
Exclusive partnership provides 319 Golf Society members with preferred Flyte benefits. FLYTE brings its regional luxury private aviation platform to members of premier private golf clubs across the United States FORT [...]
Micron Biomedical Secures $4.5 Million Federal Contract to Develop First Dissolvable Microarray Radiation/Nuclear Medical Countermeasure
27/07/2026
Next generation approach strengthens national preparedness against nuclear threats by accelerating access to time-sensitive treatments that allow for longer shelf life, simplified distribution and self-administration [...]
Glass House Brands Retains Former DEA Compliance Executive to Advise on Interstate Commerce and Export Opportunities
27/07/2026
LONG BEACH, Calif. and TORONTO, July 27, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the "Company") (CBOE CA: GLAS.A.U) (NYSE: GLAS) today announced that the Company has retained Matt Murphy, as [...]
Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer
27/07/2026
MILLBRAE, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet [...]
OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026
27/07/2026
LONDON and NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain ( [...]
Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026
27/07/2026
Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on August 11, 2026 NASHVILLE, Tenn., July 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease [...]
Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026
27/07/2026
BERKELEY HEIGHTS, N.J., July 27, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biotechnology company, today announced that [...]
Picard Medical Receives NYSE American Acceptance of Compliance Plan
27/07/2026
-Company continues advancing long-term growth strategy under accepted compliance plan- TUCSON, Ariz., July 27, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the “Company” or “Picard Medical”), [...]
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
27/07/2026
VXA-222 advances into next phase at VERAXA ZURICH, SWITZERLAND, July 27, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA” or the "Company"), an emerging leader in designing novel cancer therapies, today announced the [...]
Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026
27/07/2026
Company plans to submit an IND in the fourth quarter of 2026 and to initiate Phase 1 study by the end of 2026 WATERTOWN, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA) a clinical- [...]

Pages